Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovramilast in Moderate to Severe Acute or Recurrent Leprosy Type 2 Reaction
NCT07172659Phase 2Recruiting
- Sponsor
- Medicines Development for Global Health
- Start
- Oct 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of dovramilast in erythema nodosum leprosum (ENL), sponsored by Medicines Development for Global Health. Started Oct 2026; status: recruiting.
02
Drugs
dovramilast
03
Conditions
erythema nodosum leprosum (ENL)
Beyond the preview
Go deeper on NCT07172659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172659.